Pharmacokinetic optimisation of benzodiazepine therapy for acute seizures. Focus on delivery routes

Clinical Pharmacokinetics

Volumn 36, Issue 6, 1999, Pages 409-424

  Elisabeth, Rey ^a,b   Tréluyer, Jean Marc ^a   Pons, Gérard ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b HÔPITAL SAINT VINCENT DE PAUL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE; BRAIN RECEPTOR; CLONAZEPAM; DIAZEPAM; LORAZEPAM; MIDAZOLAM; PHENOBARBITAL; PHENYTOIN; BENZODIAZEPINE DERIVATIVE;

APNEA; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; EPILEPTIC STATE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIPID SOLUBILITY; NONHUMAN; PHARMACODYNAMICS; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RECTAL DRUG ADMINISTRATION; RESPIRATION DEPRESSION; SEIZURE; DRUG ADMINISTRATION ROUTE; REVIEW;

BENZODIAZEPINES; DRUG ADMINISTRATION ROUTES; HUMANS; SEIZURES; STATUS EPILEPTICUS;

EID: 0033143591     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199936060-00003     Document Type: Article

References (98)

1. 1. Leppik IE, Derivan AT, Homan RW, et al. Double-blind study of lorazepam and diazepam in status epilepticus. JAMA 1983; 249: 1452-4
2. 2. Gastaut J, Courjon J, Poiré R, et al. Treatment of status epilepticus with a new benzodiazepine more active than diazepam. Epilepsia 1971; 12: 197-214
3. 3. Galvin GM, Jelinek GA. Midazolam: an effective intravenous agent for seizure control. Arch Emerg Med 1987; 4: 169-72
4. 4. Kaplan SA, Jack ML, Alexander K, et al. Pharmacokinetic profile of diazepam in man following single intravenous and oral and chronic oral administrations. J Pharm Sci 1973; 62: 1788-96
5. 5. Shorvon S. Emergency treatment of status epilepticus. In: Shorvon S, editor Status epileplicus, its clinical features and treatment in children und adults, Cambridge: Cambridge University Press, 1994: 175-292
6. 6. Greenblatt DJ, Shader RI, Franke K, et al. Pharmacokinetics and bioavailability of Intravenous and intramuscular, and oral lorazepam in humans. J Pharm Sci 1979; 68: 57-63
7. 7. Allonen H, Ziegler G, Klotz U. Midazolam kinetics. Clin Pharmacol Ther 1981; 30: 653-61
8. 8. Bell DM, Richards G, Dhillon S, et al. A comparative pharmacokinetic study of intravenous and intramuscular midazolam in patients with epilepsy. Epilepsy Res 1991; 10: 183-90
9. 9. Prensky AL, Raff MC, Moore MJ, et al. Intravenous diazepam in the treatment of prolonged seizure activity. N Engl J Med 1967; 276: 779-84
10. 10. Ramsay RE, Hammond EJ, Perchalski RJ, et al. Brain uptake of phenytoin, phenobarbital and diazepam. Arch Neurol 1979; 36: 535-9
11. 11. Ferngren HG. Diazepam treatment for acute convulsions in children. Epilepsia 1974; 15: 27-37
12. 12. Remy C, Jourdil N, Villemain D, et al. Intrarectal diazepam in epileptic adults. Epilepsia 1992; 33: 353-8
13. 13. Homan RW, Walker JE, Clinical studies of torazepam in status epilepticus. In: Delgado-Escueta AV, Wasterlain CG,Treiman DM, et al., editors. Advances in neurology: status epilepticus. New York: Raven Press, 1983: 493-8
14. 14. Walker JE, Homan RW, Crawford IL. Lorazepam: a controlled trial in patients with intractable partial complex seizures. Epilepsia 1984; 25: 464-6
15. 15. Ghilain S, Van Rijekevorsel-Harmant K, Harmant J, et al. Midazolam in the treatment of epileptic seizures. J Neurol Neurosurg Psychiatry 1988; 51; 732
16. 16. Laurijssens BE, Greenblatt DJ. Pharmacokinetic-pharmacodynamic relationships for benzodiazepines. Clin Pharmacokinet 1996; 30: 52-76
17. 17. Greenblatt DJ, Ehrenberg BL, Gunderman J, et al. Pharmacokinetic and electroencephalographic study of intravenous diazepam, midazolam, and placebo. Clin Pharmacol Ther 1989; 45: 356-5
18. 18. Bührer M, Maitre PO, Crevoisier C, et al. Electroencephalographic effects of benzodiazepines: II. Pharmacodynamic modeling of the encephalographic effects of midazolam and diazepam. Clin Pharmacol Ther 1990; 48: 555-67
19. 19. Mould DR, DeFeo TM, Reele S, et al., Simultaneous modeling of the pharmacokinetics and pharmacodynamics of midazolam and diazepam. Clin Pharmacol Ther 1995; 58: 35-43
20. 20. Greenblatt DJ, Ehrenberg BL, Gunderman J, et al. Kinetic und dynamic study of intravenous lorazepam: comparison with intravenous diazepam. J Pharmacol Exp Ther 1989; 250: 134-40
21. 21. Gupta SK, Ellinwood EH, Nikaido AM, et al. Simultaneous modeling of the pharmacokinetic and pharmacodynamic properties of benzodiazepines: I. Larazepam. J Pharmacokinet Biopharm 1990; 18: 89-102
22. 22. Tedeschi G, Smith AT, Dhillon S, et al. Rate of entrance of benzodiazepines into the brain determined by eye movement recording. Br J Clin Pharmacol 1983; 15: 103-7
23. 23. Pardridge WM. Transport of small molecules through the Mood-brain barrier; biology and methodology. Adv Drug Delivery Rev 1995; 15:5-36
24. 24. Sato S. Benzodiazepines: clonazepam. In: Levy R, Mattson R, Meldrum B, editors. Antiepileptic drugs. 3rd ed. New York: Raven Press Ltd., 1989: 765-84
25. 25. Schmidt D. Benzodiazepines: diazepam. In: Levy R, Mattson R, Meldrum B, editors. Antiepileptic drugs. 3rd ed. New York: Raven Press Ltd., 1989: 735-64
26. 26. Human RW, Unwin DH. Benzodiazepines: lorazepam. In: Levy R, Mattson R, Meldrum B, editors. Antiepileptic drugs. 3rd ed. New York: Raven Press Ltd., 1989: 841-54
27. 27. Reves JG, Fragen RJ, Vinik HR, et al. Midazolam: pharmacology and uses. Anesthesiology 1985; 62: 310-24
28. 28. Bonati M, Kanto J, Tognoni G. Clinical pharmacokinetics of cerebrospinal fluid. Clin Pharmacokinet 1982; 7: 312-35
29. 29. Moschitto LJ, Greenblatt DJ. Concentration-independent plasma protein binding of benzodiazepines. J Pharm Pharmacol 1983; 35: 179-80
30. 30. El-Khordagui LK, Saleh AM, Khalil SA. Absorption of benzodiazepines on charcoal and its correlation with in vitro and in vivo data. Pharm Acta Helv 1987; 62: 28-32
31. 31. Greenblatt DJ, Arendt RM, Abernethy DR, et al. In vitro quantitation of benzodiazepine lipophilicity: relation to in vivo distribution. Br J Anaesth 1983; 55: 985-9
32. 32. Pieri L, Schaffner R, Scherschlicht R, et al. Pharmacology of midazolam. Arzneimittel Forschung 1981; 31: 2180-201
33. 33. Kanto J, Kangas L, Siirtola T. Cerebrospinal fluid of diazepam and its metabolites in man. Acta Pharmacol Toxicol 1975; 36: 328-34
34. 34. Ochs HR, Busse J, Greenblatt DJ, et al. Entry of lorazepam into cerebrospinal fluid. Br J Clin Pharmacol 1980; 10: 405-6
35. 35. Aaltonen L, Kanto J, Salo M. Cerebrospinal fluid and concentrations and serum protein binding of lorazepam and its conjugate. Acta Pharmacol Toxicol 1980; 46: 156-8
36. 36. Sjövall S, Kanto J, Himberg JJ, et al. CSF penetration and pharmacokinetics of midazolam. Eur J Clin Pharmacol 1983; 25: 247-51
37. 37. Greenblatt DJ, Miller LG, Shader RI. Clonazepam pharmacokinetics, brain uptake, and receptor interactions. J Clin Psychiatry 1987; 48: 4-11
38. 3H]flunitrazepam. Life Sci 1978; 22: 859-66
39. 39. Miller LG, Greenblatt DJ, Paul SM, et al. Benzodiazepine receptor occupancy in vivo: correlation with brain concentrations and pharmacodynamic actions. J Pharmacol Exp Ther 1987; 240: 516-22
40. 40. Macdonald RL. Benzodiazepines: mechanism of action. In: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995: 695-703
41. 41. Klotz U, Antonin KH, Bieck PR. Pharmacokinetics and plasma binding of diazepam in man, dog, rabbit, guinea pig and rat. J Pharmacol Exp Ther 1976; 199: 67-73
42. 42. Greenblatt DJ, Allen MD, Harmatz JS, et al. Diazepam disposition determinants. Clin Pharmacol Ther 1980; 27: 301-12
43. 43. Knop HJ, Van Der Kleijn E, Edmunds LC. Pharmacokinetics of clonazepam in man and laboratory animals. In: Schneider H, Janz D, Gardner-Thorpe C, et al., editors. Clinical pharmacology of anti-epileptic drugs. Berlin: Springer, 1974: 247-59
44. 44. André M, Boutroy MJ, Dubruc C, et al. Clonazepam pharmacokinetics and therapeutic efficacy in neonatal seizures. Eur J Clin Pharmacol 1986; 30: 585-9
45. 45. Kraus JW, Desmond PV, Marshall JP, et al. Effects of aging and liver disease on disposition of Iorazepam. Clin Pharmacol Ther 1978; 24: 411-9
46. 46. McDermott CA, Kowalczyk AL, Schniltzer ER, et al. Pharmacokinetics of lorazepam in critically ill neonates with seizures. J Pediatr 1992; 120: 479-83
47. 47. Heizmunn P, Eckert M, Ziegler WH. Pharmacokinetics and bioavailability of midazolam in man. Br J Clin Pharmacol 1983; 16: 43S-9S
48. 48. Payne K, Mattheyse FJ, Liebenberg D, et al. The pharmacokinetics of midazolam in pediatric patients. Eur J Clin Pharmacol 1989; 37: 267-72
49. 49. Rey E, Delaunay L, Pons G, et al. Pharmacokinetics of midazolam in children: comparative study of intranasal and intravenous administration. Eur J Clin Pharmacol 1991; 41: 355-7
50. 50. Jacqz-Aigrain E., Wood C, Robieux I. Pharmacokinetics of midazolam in critically ill neonates. Eur J Clin Pharmacol 1990; 39: 191-2
51. 51. Jung F, Richardson TH, Raucy JL, et al. Diazepam metabolism by cDNA-expressed human 2C P450s: identification of P4502C18 and P4502C19 as low Km diazepam N-demethylases. Drug Metab Dispos 1997; 25: 133-9
52. 52. Seree EJ, Pisano PJ. Placidi M, et al. Identification of the human hepatic cytochromes P450 involved in clonazepam metabolism. Fundam Clin Pharmacol 1993; 7: 69-75
53. 53. Kronbach T, Mathys D, Umenu M, et al. Oxidation of midazolam and triazolam by human liver cytochrome P450111A4. Mol Pharmacol 1989; 36: 89-96
54. 54. Elliott HW. Metabolism of lorazepam. Br J Anesth 1976; 48: 1017-23
55. 55. Magnussen I, Oxlund HRW, Alsbirk KE, et al. Absorption of diazepam in man following rectal and parenteral administration. Acta Pharmacol Toxicol 1979; 45: 87-90
56. 56. Dhillon S, Oxley J, Richens A. Bioavailability of diazepam after intravenous, oral and rectal administration in adult epileptic patients. Br J Clin Pharmacol 1982; 13: 427-32
57. 57. Milligan N, Dhillon S, Oxley J, et al. Absorption of diazepam from the rectum and its effect on interictal spikes in the EEG. Epilepsia 1982; 23: 323-31
58. 58. Agurell S, Berlin A, Ferngren H, et al. Plasma levels of diazepam after parenteral and rectal administration in children, Epilepsia 1975; 16: 277-83
59. 59. Knudsen FU. Plasma-diazepam in infants after rectal administration in solution and by suppository. Acta Pacdiatr Scand 1977; 66: 563-7
60. 60. Dulac O, Aicardi J, Key E, et al. Blood levels of diazepam after single rectal administration in infants and children. J Paediatr 1978; 36: 1039-41
61. 61. Meberg A, Langlset A, Bredesen JE, et al. Plasma concentration of diazepam and N-desmethyldiazepam in children after a single rectal or intramuscular dose of diazepam. Eur J Clin Pharmacol 1978; 14: 273-6
62. 62. Manila MAK, Ruoppi MK, Ahlström-Bengs E, et al. Diazepam in rectal solution as premedication in children, with special reference to scrum concentrations. Br J Anacsth 1981; 53: 1269-72
63. 63. Dhillon S, Ngwane E, Richens A. Rectal absorption of diazepam in epileptic children. Arch Dis Child 1982; 57: 264-7
64. 64. Jensen PK, Abild K, Poulsen MN. Serum concentration of clonazepam after rectal administration. Acta Neurol Scand 1983; 68: 417-20
65. 65. Rylance GW, Poulton J, Cherry RC, et al. Plasma concentrations of elonazepam after single rectal administration. Arch Dis Child 1986; 61: 186-8
66. 66. Graves NM, Kriel RL, Jones-Saete C. Bioavailahility of rectally administered lorazepam. Clin Neuropharm 1987; 6: 555-9
67. 67. Saint-Maurice C, Meistelman C, Rey E, et al. The pharmacokinetics of rectal midazolam for premeditation in children. Anesthesiology 1986; 65: 536-8
68. 68. Moolenaar F, Bakker S, Visser J, et al. Biopharmaceutics of rectal administration of drugs in man. IX. Comparative biopharmaceutics of diazepam after single rectal, oral, intramuscular and intravenous administration in man. Int J Pharm 1980; 5: 127-37
69. 69. Minagawa K, Miura H, Mizuno S, et al. Pharmacokinetics of rectal diazepam in the prevention of recurrent febrile convulsions. Brain Dev 1986; 8: 53-9
70. 70. Morselli PL, Principi N, Tognoni GM, et al. Diazepam elimination in premature and full term infants, and children. J Perinat Med 1973; 1: 133-44
71. 71. Treiman DM. Pharmacokinetics and clinical use of benzodiazepines in the management of status epileptieus, Epilepsia 1989; 30 Suppl. 2: S4-S10
72. 72. Treiman DM, De Giorgio CM, Ben-Menachem E, et al. Lorazepam versus phenytoin in the treatment of generalised convulsive status epilepticus: report of an ongoing study [abstract]. Neurology 1985; 35: 284
73. 73. Shaner DM, McCurdy SA, Herring MO, et al. Treatment of status epilepticus: a prospective comparison of diazepam and phenytoin versus phenobarbital and optional phenytoin. Neurology 1988; 38: 202-7
74. 74. Dieckmann RA. Rectal diazepam for prehospital pediatric status epilepticus. Ann Emerg Med 1994; 23: 216-24
75. 75. Andermann F, Cendes F, Reiher J, et al. A prospective double-blind study of the effects of intravenously administered lorazepam and diazepam in the treatment of status epilepticus [abstract]. Epilepsia 1992; 33: 3
76. 76. Chamberlain JM, Altieri MA, Futterman C, et al. A prospective, randomized study comparing intramuscular midazolam with intravenous diazepam for the treatment of seizures in children. Pediatr Emerg Care 1997; 13: 92-4
77. 77. Giang DW, McBride MC. Lorazepam versus diazepam for the treatment of status epilepticus. Pediatr Neurol 1988; 4: 358-61
78. 78. Albano A, Reisdorff EJ, Wiegenstein JG. Rectal diazepam in pediatric status epilepticus. Am J Emerg Med 1989; 70: 168-72
79. 79. Dreifuss FE, Rosman NP, Cloyd JC, et al. A comparison of rectal diazepam gel and placebo for acute repetitive seizures. N Engl J Med 1998; 338: 1869-75
80. 80. Labar DR, Ali A, Root J. High-dose intravenous lorazepam for the treatment of refractory status epilepticus. Neurology 1994; 44: 1400-3
81. 81. Kumar A, Bleck TP. Intravenous midazolam for the treatment of refractory status epilepticus. Crit Care Med 1992; 20: 483-8
82. 82. Wroblewski BA, Joseph AB. The use of intramuscular midazolam for acute seizure cessation or behavioral emergencies in patients with traumatic brain injury. Clin Neuropharmacol 1992; 15: 44-9
83. 83. Lahat E, Aladjem M, Eshel G, et al. Midazolam in treatment of epileptic seizures, Pediatr Neurol 1992; 8: 215-6
84. 84. Rivera R, Segnini M, Baltodano A, et al. Midazolam in the treatment of status epilepticus in children. Crit Care Med 1993; 21: 991-4
85. 85. Gherpelli JLD, Luccas FJC, Roitman I, et al. Midazolam for treatment of refractory neonatal seizures. Arq Neuropsiquiatr 1994; 52: 260-2
86. 86. Parent JM, Lowenstein DH. Treatment of refractory generalized status epilepticus with continuous infusion of midazolam. Neurology 1994; 44: 1837-40
87. 87. O'Regan ME, Brown JK, Clarke M. Nasal rather than rectal benzodiazepines in the management of acute childhood seizures? Dev Med Child Neurol 1996; 38: 1037-45
88. 88 Kriel RL, Cloyd JC, Hadsall RS, et al. Home use of rectal diazepam for cluster and prolonged seizures: efficacy, adverse reactions, quality of life, and cost analysis. Pediatr Neurol 1991; 7: 13-7
89. 89. Jawad S, Oxley J, Wilson J, et al. A pharmacodynamic evaluation of midazolam as an antiepileptic compound. J Neurol Neurosurg Psychiatry 1986; 49: 1050-4
90. 90. Chiulli DA, Terndrup TE, Kanter RK, The influence of diazepam or lorazepam on the frequency of endotracheal intubation in childhood status epilepticus. J Emerg Med 1991; 9: 13-7
91. 91. Van Der Kleijn E, Baars AM, Uree TB, et al. Clinical pharmacokinetics of drugs used in the treatment of status epilepticus (1983), Cited in: Levy RH, Dreifuss FE, Malison H, et al., editors. Antiepileptic drugs. 3rd ed. New York: Raven Press, 1989: 776
92. 92. Dundee JW, Halliday NJ, Harper KW, et al. Midazolam: a review of its pharmacological properties and therapeutic use. Drugs 1984; 28: 519-43
93. 93. Shorvon SD. The use of clobazam, midazolam, and nitrazepam in epilepsy. Epilepsia 1998; 39 Suppl, 1: S15-S23
94. 94. Schmidt D. How to use benzodiazepines. In: Morselli PL, Pippenger CE, Penry JK, editors. Antiepileptic drug therapy in pediatrics. New York: Raven Press, 1983: 271-80
95. 95. Bleck TP. Convulsive disorders: status epilepticus. Clin Neuropharmacol 1991; 14: 191-8
96. 96. Mitchell WG. Status epilepticus and acute repetitive seizures in children, adolescents, and young adults: etiology, outcome, and treatment. Epilepsia 1996; 37 Suppl. 1: S74-S80
97. 97. Congdon PJ, Forsythe WI. Intravenous clonazepam in the treatment of status epilepticus in children. Epilepsia 1980; 21: 97-102
98. 98. Leppik IE. Status epilepticus. In: Willie E, editor. The treatment of epilepsy: principles and practice. Philadelphia: Lea & Febiger. 1993: 678-85